Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

New research finds that cancer cells with a more easily deformed nucleus are more sensitive to DNA-damaging drugs.

Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a ...

Cancer cells with a cell nucleus that is easily deformed are more sensitive to drugs that damage DNA. These are the findings of a new study by researchers at Linköping University in Sweden.

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its Series D round will help advance ongoing mid-stage studies.

UTEP researchers identify Claudin-4 protein as a target to improve immune response against aggressive ovarian cancer.

Please provide your email address to receive an email when new articles are posted on . Saruparib at 60 mg/day demonstrated deep, durable responses with a high response rate and tumor reduction in ...

Scientists at The University of Texas at El Paso have identified a promising new target in the battle against high-grade ...

Recent developments in PARP inhibitor combinations and antibody-drug-conjugates are changing the landscape of ovarian cancer treatment. In spring 2021, Kathy Ventre, 56, of Cincinnati, sensed ...